[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CX13-608 in the treatment of relapsed or refractory multiple myeloma
主要目的:评估复发或难治性多发性骨髓瘤患者静脉给予CX13-608的耐受性和安全性;确定CX13-608静脉给药在复发或难治性多发性骨髓瘤患者中的剂量限制性毒性(DLT)和最大耐受剂量(MTD),为II期临床试验给药方案和给药剂量提供依据。
[Translation] Primary objective: To evaluate the tolerability and safety of intravenous CX13-608 in patients with relapsed or refractory multiple myeloma; to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of intravenous CX13-608 in patients with relapsed or refractory multiple myeloma, and to provide a basis for the dosing regimen and dosage of Phase II clinical trials.